STOCK TITAN
  1. Home
  2. Sec-filings
  3. RCEL
  4. [Form 4] AVITA Medical, Inc. Insider Trading Activity

AVITA Medical (RCEL) director Michael Tarnoff receives RSU and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AVITA Medical, Inc. director Michael E. Tarnoff reported equity awards in the form of restricted stock units (RSUs) and stock options. On August 6, 2025, he received 26,250 RSUs and 19,063 stock options with an exercise price of $5.36 per share, vesting in three equal annual installments after the first anniversary. On January 20, 2026, he received an additional 22,214 RSUs that vest 12 months after the grant date and 16,133 stock options with an exercise price of $3.77 per share, also vesting in three equal annual installments beginning one year after grant. These awards were approved by the Board and were subject to stockholder approval obtained on June 3, 2026. Following the most recent RSU grant, Tarnoff directly holds 48,464 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Tarnoff Michael E
Role null
Type Security Shares Price Value
Grant/Award Stock Options (Right to Buy) 16,133 $0.00 --
Grant/Award Common Stock 22,214 $0.00 --
Grant/Award Stock Options (Right to Buy) 19,063 $0.00 --
Grant/Award Common Stock 26,250 $0.00 --
Holdings After Transaction: Stock Options (Right to Buy) — 16,133 shares (Direct, null); Common Stock — 48,464 shares (Direct, null)
Footnotes (1)
  1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of August 6, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. Includes unvested RSUs Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. On August 6, 2025, the Board of Directors approved a grant of 19,063 options to acquire 19,063 shares of Common Stock of the Company to Dr. Tarnoff as a new non-executive director, with an effective grant date of August 6, 2025 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date. On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
RSU grant Aug 6 2025 26,250 RSUs Restricted stock units granted August 6, 2025
Option grant Aug 6 2025 19,063 options at $5.36 Stock options granted August 6, 2025, exercise price $5.36/share
RSU grant Jan 20 2026 22,214 RSUs Restricted stock units granted January 20, 2026
Option grant Jan 20 2026 16,133 options at $3.77 Stock options granted January 20, 2026, exercise price $3.77/share
Shares held after grant 48,464 shares Common shares directly held after January 20, 2026 RSU grant
Option expiry 2035 19,063 options expiring 2035-08-06 Expiration date for August 6, 2025 stock option grant
Option expiry 2036 16,133 options expiring 2036-01-20 Expiration date for January 20, 2026 stock option grant
restricted stock units financial
"Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an exercise price equal to the closing price of a share of Common Stock"
exercise price financial
"an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
time-based vesting criteria financial
"that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments"
contingent right financial
"each RSU representing a contingent right to be issued one share of Common Stock of the Company"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tarnoff Michael E
(Last)(First)(Middle)
C/O AVITA MEDICAL
28159 AVENUE STANFORD, SUITE 220
(Street)
VALENCIA CALIFORNIA 91355
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/06/2025A26,250A(1)26,250(2)D
Common Stock01/20/2026A22,214A(3)48,464(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$5.36(4)08/06/2025A19,063 (5)08/06/2035Common Stock19,063$019,063D
Stock Options (Right to Buy)$3.77(6)01/20/2026A16,13301/20/202701/20/2036Common Stock16,133$016,133D
Explanation of Responses:
1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of August 6, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
2. Includes unvested RSUs
3. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
4. On August 6, 2025, the Board of Directors approved a grant of 19,063 options to acquire 19,063 shares of Common Stock of the Company to Dr. Tarnoff as a new non-executive director, with an effective grant date of August 6, 2025 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
5. These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.
6. On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
/s/ Nicole Kelsey, by power of attorney06/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did AVITA Medical (RCEL) director Michael Tarnoff report?

Director Michael Tarnoff reported equity awards, not open-market trades. He received restricted stock units and stock options in AVITA Medical common stock as part of his compensation, with specific grants on August 6, 2025 and January 20, 2026, subject to stockholder approval.

How many AVITA Medical (RCEL) shares does Michael Tarnoff hold after these grants?

After the January 20, 2026 RSU grant, Michael Tarnoff directly holds 48,464 shares of AVITA Medical common stock. This figure includes previously granted restricted stock units that remain unvested, as indicated by the filing’s note that his holdings include unvested RSUs.

What restricted stock unit awards did RCEL grant to Michael Tarnoff?

Tarnoff received 26,250 restricted stock units on August 6, 2025 and 22,214 restricted stock units on January 20, 2026. Each RSU represents a contingent right to one AVITA Medical common share, subject to time-based vesting conditions detailed in the filing’s footnotes.

What stock options did AVITA Medical (RCEL) grant to Michael Tarnoff?

AVITA Medical granted Tarnoff 19,063 stock options on August 6, 2025 with a $5.36 exercise price and 16,133 options on January 20, 2026 with a $3.77 exercise price. Both option grants vest in three equal annual installments beginning one year after the grant date.

Were Michael Tarnoff’s AVITA Medical (RCEL) equity awards subject to stockholder approval?

Yes. The RSU and stock option grants approved on August 6, 2025 and January 5, 2026 were subject to AVITA Medical stockholder approval. The filing states that stockholders approved these grants on June 3, 2026, after which the awards became effective under their described terms.

How do the AVITA Medical (RCEL) RSUs granted to Michael Tarnoff vest?

The August 6, 2025 RSUs vest in three equal annual installments starting 12 months after the grant date. The January 20, 2026 RSUs vest in a single installment 12 months after that grant date, assuming the applicable time-based vesting criteria are satisfied as described.